evocalcet

Small moleculeexperimental

Clinical trial activity

9 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
6
Phase 3
5
Phase 4
0

Earliest trial started Aug 1, 2013 (NCT01935856)

Timeline

2010s

  1. Jan 1, 2013

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2014

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2015

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

C[C@@H](N[C@H]1CCN(c2ccc(CC(=O)O)cc2)C1)c1cccc2ccccc12
Mol. weight
374.48 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • evocalcet
  • khk7580

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04206657Phase 1Dec 31, 2019Kyowa Hakko Kirin
NCT03822507Phase 3Apr 9, 2019Kyowa Hakko Kirin
NCT03280264Phase 3Aug 30, 2017Kyowa Hakko Kirin
NCT02549404Phase 3Sep 1, 2015Kyowa Hakko Kirin
NCT02549391Phase 2/Phase 3 (Phase 3)Sep 1, 2015Kyowa Hakko Kirin
NCT02549417Phase 3Sep 1, 2015Kyowa Hakko Kirin
NCT02216656Phase 2Jul 1, 2014Kyowa Hakko Kirin
NCT02143271Phase 1May 1, 2014Kyowa Hakko Kirin
NCT01935856Phase 1/Phase 2 (Phase 2)Aug 1, 2013Kyowa Hakko Kirin
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Kyowa Hakko KirinFor profit9932013
1 organizations
Page 1 / 1